Ali Erginay · enciclopedia

Publicaciones › Edema macular diabético y sus tratamientos

CHANGE IN RETINAL PERFUSION WITH AFLIBERCEPT FOR CENTRAL RETINAL VEIN OCCLUSION: The Two-Year Prospective Observational HERMES Study

CAMBIO EN LA PERFUSIÓN RETINIANA CON AFLIBERCEPT PARA OCLUSIÓN DE LA VENA CENTRAL RETINIANA: El estudio observacional prospectivo de dos años HERMES

Año2025
FuenteRetina (Philadelphia, Pa.)
Tipoarticle · Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't
Autores (14)Agnès Glacet-Bernard, Jean-François Girmens, Florence Coscas, Sylvia Nghiem-Buffet, Christophe Morel, Ali Erginay, Michel Weber, Xavier Wang, Camille Jung, Salomon-Yves Cohen, Tristan Aubert, Rocio Blanco-Garavito, Eric H Souied, Alexandra Miere
Posición de Erginay6 de 14
Citas2 (OpenAlex)
EnlacesDOI 10.1097/iae.0000000000004425 · PubMed 39933139 · OpenAlex · Texto completo en acceso abierto
LíneasEdema macular diabético y sus tratamientos Enfermedades vasculares, genéticas e inflamatorias de la retina Interfase vitreomacular, agujero macular y miopía alta Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió cómo cambia la perfusión retiniana en pacientes con oclusión de la vena central retiniana tratados con inyecciones de aflibercept. Los resultados mostraron que aunque la agudeza visual mejoró, la perfusión en la periferia de la retina empeoró con el tiempo. La densidad de los capilares en la mácula se mantuvo estable.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

PURPOSE: To analyze retinal perfusion using ultrawide-field fluorescein angiography and optical coherence tomography angiography, in patients with central retinal vein occlusion treated by intravitreal injection of aflibercept. METHODS: Single-arm, multicenter, prospective, observational study. Treatment-naive eyes with central retinal vein occlusion initiated therapy with aflibercept. Ultrawide-field fluorescein angiography with correction of projection distortion and optical coherence tomography angiography were performed at baseline (M0), M3, M12, and M24. RESULTS: Fifty-six eyes were included. Visual acuity improved by 16 ETDRS letters at M12 ( P < 0.001), while mean central subfield thickness decreased from 801 µ m at M0 to 352 µ m at M12 ( P < 0.001). The ischemic index on ultrawide-field fluorescein angiography increased from 17% at M0 to 23% at M3, and to 36% at M24. Ischemic central retinal vein occlusion accounted for 18% at M0, 25% at M3, and 39% at M24 ( P < 0.05). Vascular leakage was only present in 21% of eyes at M12. The density of the superficial and deep capillary plexus remained stable, but the foveal avascular zone enlarged from 0.37 mm 2 at M0 to 0.61 mm 2 at M24 ( P = 0.02). No cases of reperfusion were observed. The mean number of injections at M12 was 7.0 ± 3.6. CONCLUSION: Changes in retinal perfusion were characterized by worsening perfusion in the periphery, while macular capillaries maintained a generally stable density at M24, even in ischemic central retinal vein occlusion. These findings support the need for regular monitoring of peripheral retinal perfusion in treated patients to detect silent progression of nonperfusion, which may lead to neovascular complications, while visual acuity is maintained over the long term, likely due to the preserved macular capillary density.

Términos MeSH

Aged Aged, 80 and over Female Humans Male Middle Aged Angiogenesis Inhibitors Fluorescein Angiography Follow-Up Studies Fundus Oculi Intravitreal Injections Prospective Studies Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins Retinal Vein Occlusion Retinal Vessels Time Factors Tomography, Optical Coherence Visual Acuity